Table 2 The risk factors of mortality among patients (n = 164)
Mortality (n = 96) | Survival (n = 68) | Univariate analysis | ||
|---|---|---|---|---|
Risk ratio (%95 CI) | p value | |||
Demographic features | ||||
Age | 1.863 (1.251–2.775) | 0.001 | ||
< 64 | 39 | 45 | ||
> 65 | 57 | 23 | ||
Gender | 1.380 (0.0939–2.028) | 0.093 | ||
Male | 48 | 43 | ||
Female | 48 | 25 | ||
Comorbidity | ||||
Diabetes mellitus | 23 | 7 | 2.746 (1.103–6.833) | 0.026 |
Chronic obstructive pulmonary diseases | 12 | 6 | 1.476 (0.525–4.149) | 0.458 |
Congestive heart failure | 12 | 8 | 1.071 (0.413–2.781) | 0.887 |
Chronic liver failure | 11 | 2 | 4.271 (0.915–19.932) | 0.047 |
Corticosteroid usage | 8 | 11 | 0.471 (0.179–1.242) | 0.122 |
Neutropenia | 4 | 2 | 1.435 (0.255–8.065) | 0.680 |
Malignancy | 27 | 12 | 1.826 (0.849–3.924) | 0.120 |
Chemotherapy | 14 | 3 | 3.699 (1.020–13.421) | 0.035 |
Invasive procedures | ||||
Mechanical ventilation | 67 | 38 | 1.824 (0.955–3.484) | 0.067 |
Central catheterisation | 74 | 54 | 0.872 (0.409–1.858) | 0.723 |
Urinary catheterisation | 94 | 66 | 1.424 (0.196–10.368) | 0.726 |
Drugs used before diagnosis | ||||
Penicillin and derivatives | 29 | 15 | 1.529 (0.744–3.142) | 0.246 |
3rd generation cephalosporins | 32 | 23 | 1.067 (0.542–2.099) | 0.852 |
Fluoroquinolones | 22 | 5 | 3.646 (1.30–10.227) | 0.010 |
Aminoglycosides | 7 | 2 | 2.512 (0.504–12.510) | 0.246 |
Carbapenems | 49 | 37 | 0.840 (0.438–1.610) | 0.599 |
Colistin | 3 | 5 | 0.391 (0.090–1.699) | 0.196 |